ConductScience.org, home
Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease
API referenceFor AI assistants

Trial · NCT06207331

Registered outcomes19

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 19 of 19

Download this page as JSON
ListOutcomeTime frameDescription
PrimaryFVC10 minutes and 30 minutes after administration of nebulized drugsForced vital capacity
SecondaryFEV110 minutes and 30 minutes after administration of nebulized drugsForced expiratory volume in one second
SecondaryFEV1/FVC%10 minutes and 30 minutes after administration of nebulized drugsForced expiratory volume in one second/Forced vital capacity
SecondaryMMEF10 minutes and 30 minutes after administration of nebulized drugsmaximal mid-expiratory flow curve
SecondaryPEF10 minutes and 30 minutes after administration of nebulized drugsPeak expiratory flow
SecondaryBEV10 minutes and 30 minutes after administration of nebulized drugsBack-extrapolation volume
SecondaryFET10 minutes and 30 minutes after administration of nebulized drugsForced expiratory time
SecondaryVC10 minutes and 30 minutes after administration of nebulized drugsVital capacity
SecondaryFEV1/VC10 minutes and 30 minutes after administration of nebulized drugsForced expiratory volume in one second/vital capacity
SecondaryFEF25%，FEF50%，FEF75%，10 minutes and 30 minutes after administration of nebulized drugsforced expiratory flow at 25%, 50%, and 75% of FVC exhaled
SecondaryPIF10 minutes and 30 minutes after administration of nebulized drugspeak inspiratory flow
SecondaryFIVC10 minutes and 30 minutes after administration of nebulized drugsforced inspiratory vital capacity
SecondaryFIF25, FIF50, FIF7510 minutes and 30 minutes after administration of nebulized drugsforced inspiratory flow at 25%, 50%, and 75% of FIVC
SecondaryFIV110 minutes and 30 minutes after administration of nebulized drugsforced inspiratory volume in 1 second
SecondaryMVV10 minutes and 30 minutes after administration of nebulized drugsmaximal ventilatory volume
SecondaryRichmond Agitation-Sedation Scale (RASS)10 minutes and 30 minutes after administration of nebulized drugs
RASS is a 10-point scale, with four levels of anxiety or agitation (+1 to +4 \[combative\]), one level to denote a calm and alert state (0), and 5 levels of sedation (-1 to -5) culminating in unarousable (-5).
Secondaryheart rate10 minutes and 30 minutes after administration of nebulized drugsheart rate (beat per min)
SecondarySystolic and diastolic blood pressures10 minutes and 30 minutes after administration of nebulized drugsSystolic and diastolic blood pressures (mmHg)
SecondarySPO210 minutes and 30 minutes after administration of nebulized drugsPulse oximetry (SpO2)

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06207331/registered

API referenceFor AI assistants